Cresco Labs Inc. to Post FY2024 Earnings of ($0.11) Per Share, Echelon Wealth Partners Forecasts (OTCMKTS:CRLBF)

Cresco Labs Inc. (OTCMKTS:CRLBFGet Rating) – Research analysts at Echelon Wealth Partners issued their FY2024 EPS estimates for shares of Cresco Labs in a research note issued to investors on Wednesday, May 24th. Echelon Wealth Partners analyst A. Semple anticipates that the company will earn ($0.11) per share for the year. Echelon Wealth Partners has a “Hold” rating on the stock. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.14) per share.

Other research analysts also recently issued research reports about the company. Piper Sandler downgraded Cresco Labs from an “overweight” rating to a “neutral” rating in a report on Monday, February 27th. Stifel Nicolaus reduced their price target on shares of Cresco Labs from C$2.75 to C$2.50 in a report on Friday, March 17th. Roth Capital cut shares of Cresco Labs from a “buy” rating to a “neutral” rating in a research note on Friday, March 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $14.25 price objective on shares of Cresco Labs in a research note on Friday, February 24th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to, Cresco Labs currently has a consensus rating of “Hold” and an average target price of $6.82.

Cresco Labs Price Performance

Shares of OTCMKTS CRLBF opened at $1.70 on Friday. The stock’s 50-day simple moving average is $1.55 and its two-hundred day simple moving average is $2.02. The firm has a market capitalization of $459.05 million, a P/E ratio of -2.39 and a beta of 2.76. Cresco Labs has a twelve month low of $1.30 and a twelve month high of $4.45. The company has a quick ratio of 0.68, a current ratio of 1.16 and a debt-to-equity ratio of 1.06.

Cresco Labs (OTCMKTS:CRLBFGet Rating) last posted its quarterly earnings data on Tuesday, March 21st. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The firm had revenue of $199.58 million during the quarter, compared to analysts’ expectations of $204.47 million. Cresco Labs had a negative net margin of 25.16% and a negative return on equity of 8.08%.

About Cresco Labs

(Get Rating)

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand.

Further Reading

Earnings History and Estimates for Cresco Labs (OTCMKTS:CRLBF)

Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with's FREE daily email newsletter.